Amylyx Pharmaceuticals Launches Avexitide Access Program
CAMBRIDGE, Mass., United States – May 5, 2026 Amylyx Pharmaceuticals Inc. has announced the launch of a U.S. Expanded...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., United States – May 5, 2026 Amylyx Pharmaceuticals Inc. has announced the launch of a U.S. Expanded...
RAHWAY, New Jersey, United States — December 19, 2025 — Merck & Co., known globally as MSD, has reached...
Budapest / London, September 29, 2025 Gedeon Richter and Hikma announced that the U.S. Food and Drug Administration (FDA)...
